1320 related articles for article (PubMed ID: 8520093)
1. Comparative evaluation of the safety and efficacy of HMG-CoA reductase inhibitor monotherapy in the treatment of primary hypercholesterolemia.
Hsu I; Spinler SA; Johnson NE
Ann Pharmacother; 1995; 29(7-8):743-59. PubMed ID: 8520093
[TBL] [Abstract][Full Text] [Related]
2. Atorvastatin in the treatment of primary hypercholesterolemia and mixed dyslipidemias.
Yee HS; Fong NT
Ann Pharmacother; 1998 Oct; 32(10):1030-43. PubMed ID: 9793596
[TBL] [Abstract][Full Text] [Related]
3. Pharmacodynamics and pharmacokinetics of the HMG-CoA reductase inhibitors. Similarities and differences.
Lennernäs H; Fager G
Clin Pharmacokinet; 1997 May; 32(5):403-25. PubMed ID: 9160173
[TBL] [Abstract][Full Text] [Related]
4. [Cardiovascular pharmacology (VIII). The role of HMG CoA reductase inhibitors in the current treatment of hyperlipidemias].
Carmena R
Rev Esp Cardiol; 1995 Jan; 48(1):59-65. PubMed ID: 7878284
[No Abstract] [Full Text] [Related]
5. A review of clinical trials comparing HMG-CoA reductase inhibitors.
Illingworth DR; Tobert JA
Clin Ther; 1994; 16(3):366-85; discussion 365. PubMed ID: 7923304
[TBL] [Abstract][Full Text] [Related]
6. Benefits and risks of HMG-CoA reductase inhibitors in the prevention of coronary heart disease: a reappraisal.
Pedersen TR; Tobert JA
Drug Saf; 1996 Jan; 14(1):11-24. PubMed ID: 8713485
[TBL] [Abstract][Full Text] [Related]
7. Efficacy of 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitors in the treatment of patients with hypercholesterolemia: a meta-analysis of clinical trials.
Kong SX; Crawford SY; Gandhi SK; Seeger JD; Schumock GT; Lam NP; Stubbings J; Schoen MD
Clin Ther; 1997; 19(4):778-97. PubMed ID: 9377621
[TBL] [Abstract][Full Text] [Related]
8. Interactions with hydroxymethylglutaryl-coenzyme A reductase inhibitors.
Garnett WR
Am J Health Syst Pharm; 1995 Aug; 52(15):1639-45. PubMed ID: 7583826
[TBL] [Abstract][Full Text] [Related]
9. Cost-effectiveness analysis of cholesterol-lowering therapies in Spain.
Plans-Rubió P
Am J Cardiovasc Drugs; 2006; 6(3):177-88. PubMed ID: 16780391
[TBL] [Abstract][Full Text] [Related]
10. Fluvastatin: a review of its pharmacology and use in the management of hypercholesterolaemia.
Plosker GL; Wagstaff AJ
Drugs; 1996 Mar; 51(3):433-59. PubMed ID: 8882381
[TBL] [Abstract][Full Text] [Related]
11. [Comparison of 2 cholesterol synthesis inhibitors (simvastatin and pravastatin)].
Golay A; Lehmann T; James R; Pometta D
Schweiz Med Wochenschr; 1993 Aug; 123(33):1553-8. PubMed ID: 8372340
[TBL] [Abstract][Full Text] [Related]
12. Comparative efficacy study of atorvastatin vs simvastatin, pravastatin, lovastatin and placebo in type 2 diabetic patients with hypercholesterolaemia.
Gentile S; Turco S; Guarino G; Sasso CF; Amodio M; Magliano P; Salvatore T; Corigliano G; Agrusta M; De Simone G; Gaeta I; Oliviero B; Torella R
Diabetes Obes Metab; 2000 Dec; 2(6):355-62. PubMed ID: 11225965
[TBL] [Abstract][Full Text] [Related]
13. Pharmaco-economic assessment of the HMG-CoA reductase inhibitors.
Smart AJ; Walters L
S Afr Med J; 1994 Dec; 84(12):834-7. PubMed ID: 7570232
[TBL] [Abstract][Full Text] [Related]
14. Comparative dose efficacy study of atorvastatin versus simvastatin, pravastatin, lovastatin, and fluvastatin in patients with hypercholesterolemia (the CURVES study).
Jones P; Kafonek S; Laurora I; Hunninghake D
Am J Cardiol; 1998 Mar; 81(5):582-7. PubMed ID: 9514454
[TBL] [Abstract][Full Text] [Related]
15. Simvastatin. A reappraisal of its pharmacology and therapeutic efficacy in hypercholesterolaemia.
Plosker GL; McTavish D
Drugs; 1995 Aug; 50(2):334-63. PubMed ID: 8521762
[TBL] [Abstract][Full Text] [Related]
16. Low-density lipoprotein cholesterol (LDL-C) levels and LDL-C goal attainment among elderly patients treated with rosuvastatin compared with other statins in routine clinical practice.
Harley CR; Gandhi S; Blasetto J; Heien H; Sasane R; Nelson SP
Am J Geriatr Pharmacother; 2007 Sep; 5(3):185-94. PubMed ID: 17996658
[TBL] [Abstract][Full Text] [Related]
17. Hypolipidemic effects of HMG-CoA reductase inhibitors in patients with hypercholesterolemia.
Illingworth DR; Bacon S
Am J Cardiol; 1987 Oct; 60(12):33G-42G. PubMed ID: 3314447
[TBL] [Abstract][Full Text] [Related]
18. HMG CoA reductase inhibitors as lipid-lowering agents: five years experience with lovastatin and an appraisal of simvastatin and pravastatin.
Maher VM; Thompson GR
Q J Med; 1990 Feb; 74(274):165-75. PubMed ID: 2111917
[TBL] [Abstract][Full Text] [Related]
19. Treatment of childhood hypercholesterolemia with HMG-CoA reductase inhibitors.
Duplaga BA
Ann Pharmacother; 1999 Nov; 33(11):1224-7. PubMed ID: 10573325
[TBL] [Abstract][Full Text] [Related]
20. An economic analysis of the Atorvastatin Comparative Cholesterol Efficacy and Safety Study (ACCESS).
Smith DG; McBurney CR
Pharmacoeconomics; 2003; 21 Suppl 1():13-23. PubMed ID: 12648031
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]